Economic Calendar

Tuesday, August 26, 2008

American Eagle, Biogen, Marvell Technology: U.S. Equity Preview

Share this history on :

By Nick Baker

Aug. 26 (Bloomberg) -- The following companies may have unusual price changes in U.S. trading. Stock symbols are in parentheses, and share prices are as of 8:10 a.m. unless stated otherwise.

American Eagle Outfitters Inc. (AEO US) retreated 4.3 percent to $13.15. The U.S. retailer of clothing for 15- to 25- year-olds said third-quarter profit will be as low as 31 cents a share, or 23 percent lower than the average analyst estimate in a Bloomberg survey.

BankUnited Financial Corp. (BKUNA US): Florida's largest bank may lose its ``well-capitalized'' status under federal rules for financial strength unless it attracts at least $400 million of new capital. BankUnited lost 1.2 percent to $1.59 yesterday.

Biogen Idec Inc. (BIIB US): The company and Elan Corp. (ELN US) are working on revisions to prescribing information for the multiple sclerosis drug Tysabri to show that a rare brain infection may occur in patients taking the medicine as a sole therapy. Biogen climbed 2.1 percent to $53.48 yesterday, while Elan added 4.9 percent to $14.25.

Lorillard Inc. (LO US): The cigarette maker spun off in June by Loews Corp. (L US) is the ``best-positioned'' company in the industry, Goldman Sachs Group Inc. analyst Judy Hong wrote in a report. The shares slipped 0.2 percent to $72 yesterday.

Marvell Technology Group Ltd. (MRVL US) declined 4.3 percent to $15. The maker of chips for the BlackBerry and iPhone was cut to ``hold'' from ``buy'' by Jefferies Group Inc. analyst Adam Benjamin.

Take-Two Interactive Software Inc. (TTWO US): Electronic Arts Inc. (ERTS US), the second-largest video-game publisher, signed a confidentiality agreement with Take-Two, opening the way for talks about a possible acquisition. Take-Two slipped less than 0.1 percent to $24.46 yesterday, while Electronic Arts declined 2 percent to $46.82.

To contact the reporter on this story: Nick Baker in New York at nbaker7@bloomberg.net.


No comments: